ERNAW
Ernexa Therapeutics Inc.
NASDAQ · Financial Services · Asset Management · US
$0.03
+0.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 582.0K | 68.0K | — |
| Cost of Revenue | 225.0K | 263.0K | 96.0K | 236.0K | — |
| Gross Profit | (225.0K) | (263.0K) | 486.0K | (168.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 6.4M | 4.2M | 4.6M | 5.9M | 10.4M |
| SG&A Expense | 5.1M | 4.9M | 13.1M | 14.6M | 16.6M |
| General & Admin Expense | 1.3M | — | 13.1M | 14.6M | 16.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (1.6M) | 461.0K | 6.3M |
| Total Operating Expenses | 11.5M | 9.1M | 16.2M | 21.0M | 33.2M |
| Cost and Expenses | 11.7M | 9.3M | 16.3M | 21.2M | 33.2M |
| Operating Income (EBIT) | (11.7M) | (9.3M) | (15.7M) | (21.1M) | (33.2M) |
| Non-Operating | |||||
| Interest Income | 150.0K | 83.0K | 249.0K | 138.0K | — |
| Interest Expense | — | 27.0K | 6.8M | 614.0K | 30.0K |
| Net Interest Income | 150.0K | 56.0K | (6.5M) | (476.0K) | (30.0K) |
| Other Non-Op Income/Expense | (616.0K) | (4.8M) | (28.8M) | (536.0K) | 8.7M |
| Non-Operating Income (excl Interest) | (95.0K) | — | 22.1M | (78.0K) | (8.7M) |
| EBT (Pre-Tax Income) | (12.4M) | (14.1M) | (44.5M) | (21.7M) | (24.5M) |
| Income Tax Expense | (96.0K) | (45.0K) | 30.0K | (3.0K) | 45.0K |
| Bottom Line | |||||
| Net Income | (12.3M) | (14.1M) | (44.5M) | (21.7M) | (24.6M) |
| Earnings from Cont. Ops | (12.3M) | (14.1M) | (44.5M) | (21.7M) | (24.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.3M) | (14.1M) | (44.6M) | (21.7M) | (24.6M) |
| Per Share | |||||
| Basic EPS | ($18.93) | ($55.89) | ($39.25) | ($102.00) | ($201.50) |
| Diluted EPS | ($18.93) | ($55.89) | ($39.25) | ($102.00) | ($201.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.51 | $0.32 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.2M | 252280 | 1.1M | 212560 | 122040 |
| Diluted Shares Outstanding | 1.2M | 252280 | 1.1M | 212560 | 122040 |
| Profitability Metrics | |||||
| EBITDA | (11.4M) | (9.1M) | (36.1M) | (19.9M) | (24.0M) |
| D&A | 225.0K | 263.0K | 1.6M | 1.1M | 497.0K |
| EBIT | (11.6M) | (9.3M) | (37.8M) | (21.1M) | (24.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026